Peer-reviewed veterinary case report
Survival and side effects of doxorubicin in dogs with splenic cancer
By Teske, E et al.·Published in Veterinary and comparative oncology·2011·Department of Clinical Sciences of Companion Animals, Netherlands·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A randomized controlled study into the efficacy and toxicity of pegylated liposome encapsulated doxorubicin as an adjuvant therapy in dogs with splenic haemangiosarcoma.
- Species:
- dog
Plain-English summary
A group of dogs with splenic hemangiosarcoma (a type of cancer) received either pegylated liposome encapsulated doxorubicin (PL-DOX) or standard doxorubicin after having their spleens removed. The study found that both treatments had similar effects on survival, with an average survival time of about 166 days. Some dogs treated with PL-DOX experienced skin reactions and allergic reactions, but there were no heart-related issues noted. Overall, both treatments provided comparable outcomes for these dogs.
People also search for: dog splenic hemangiosarcoma treatment · doxorubicin side effects in dogs · cancer treatment for dogs with splenic tumors
Abstract
Safety and efficacy of pegylated liposome encapsulated doxorubicin (PL-DOX) was compared with free doxorubicin as an adjuvant monotherapy in dogs with splenic haemangiosarcoma after splenectomy in a randomized prospective clinical trial. A total of 17 dogs in each group were treated. No significant difference in survival between the two treatments was found. The calculated median overall survival time for the 34 dogs was 166 days [95% confidence interval (CI) 148-184]. The ½ year and one-year survival was 41.2% (95% CI 24.8-56.9) and 22.7% (95% CI 9.9-37.4), respectively. In dogs treated with PL-DOX, a desquamating dermatitis like palmar-plantar erythrodysesthesia (PPES) was seen in two dogs, while three other dogs showed anaphylactic reactions. Cardiotoxicity was not seen in either treatment groups.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22077409/